Design and Antimalarial Evaluation of Polydopamine-Modified Methyl Artelinate Nanoparticles
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00520 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Qingxia Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shanxi Medical University, Taiyuan 030001, China. Hauptthemen laut MEDLINE: Indoles, Antimalarials, Nanoparticles, Polymers. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanxi Province.
Abstract (Originalsprache)
Targeted nanodrug delivery systems are highly anticipated for the treatment of malaria. It is known that Plasmodium can induce new permeability pathways (NPPs) on the membrane of infected red blood cells (iRBCs) for their nutrient uptake. The NPPs also enable the uptake of nanoparticles (NPs) smaller than 80 nm. Additionally, Plasmodium maintains a stable, slightly acidic, and reductive internal environment with higher glutathione (GSH) levels. Based on this knowledge, methyl artelinate (MA, a prodrug-like derivative of dihydroartemisinin) nanoparticles (MA-PCL-NPs) were developed using poly(ethylene glycol)-b-poly(ε-caprolactone) (mPEG-PCL) by a thin-film dispersion method and were further coated with polydopamine (PDA) to obtain MA-PCL@PDA-NPs with a particle size of ∼30 nm. The biomaterial PDA can be degraded in slightly acidic and reductive environments, thereby serving as triggers for drug release. MA could generate reactive oxygen species and decrease GSH levels, consequently causing parasite damage. The in vitro release experiment results indicated that the cumulative release percentage of MA from MA-PCL@PDA-NPs was considerably higher in phosphate buffer with 10 mM GSH at pH 5.5 (88.10%) than in phosphate buffer without GSH at pH 7.4 (16.98%). The green fluorescence within iRBCs of coumarin 6, the probe of NPs (C6-PCL@PDA-NPs), could be reduced significantly after adding the NPP inhibitor furosemide (p < 0.001), which demonstrated that MA-PCL@PDA-NPs could be ingested into iRBCs through NPPs. In vivo antimalarial pharmacodynamics in Plasmodium berghei K173-bearing mice showed that the inhibition ratio of MA-PCL@PDA-NPs (93.96%) was significantly higher than that of commercial artesunate injection (AS-Inj, 63.33%). The above results showed that the developed MA-PCL@PDA-NPs possessed pH-GSH dual-responsive drug release characteristics and targeting efficacy for iRBCs, leading to higher antimalarial efficacy against Plasmodium.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
- Shanxi Provincial Key Laboratory of Drug Synthesis and Novel Pharmaceutical Preparation Technology, Shanxi Medical University, Taiyuan 030001, China.
- Shanxi Provincial People's Hospital, Taiyuan 030012, China.
- Medicinal Basic Research Innovation Center of Chronic Kidney Disease, Ministry of Education, Shanxi Medical University, Taiyuan 030001, China.
ORCID-Profile: Qingxia Li, Bin Zheng, Shuqiu Zhang
Förderung
- National Natural Science Foundation of China
- Shanxi Province
Zitieren
APA
Li, Q., Wang, R., Han, S., Shi, N., Yang, J., Ping, C., Chai, L., Wang, R., Zheng, B., Ren, G., & Zhang, S. (2024). Design and Antimalarial Evaluation of Polydopamine-Modified Methyl Artelinate Nanoparticles. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00520
Vancouver
Li Q, Wang R, Han S, Shi N, Yang J, Ping C, et al. Design and Antimalarial Evaluation of Polydopamine-Modified Methyl Artelinate Nanoparticles. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00520
BibTeX
@article{Li2024,
author = {Li, Qingxia and Wang, Rongrong and Han, Shuqi and Shi, Nan and Yang, Jiaqi and Ping, Canqi and Chai, Liqing and Wang, Ruili and Zheng, Bin and Ren, Guolian and Zhang, Shuqiu},
title = {Design and Antimalarial Evaluation of Polydopamine-Modified Methyl Artelinate Nanoparticles},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00520}
}
EUVIMED